UEGJournal Abstracts 2021 - 240

Tuesday, October 5, 2021
Monday, October 4, 2021
Sunday, October 3, 2021
tant clinical impact, since DILI patients presenting with ALF and any of the
above-mentioned risk factors should be evaluated early for OLT, while OLT
might be avoided in patients who are at lower risk of OLT or death.
AUROC Sensitivity Specificity PPV NPV + LR - LR
Platelet count
< 210*109
/L
INR > 1.74
MELD ≥ 23
CHE < 4.1
kU/L
MELD/CHE
> 5.6
INR/CHE >
0.54
INR/
(CHE*platelet
count) > 0.003
MELD/
(CHE*platelet
count) > 0.03
0.91
92.3 %
93.3 % 92.3 % 93.3 % 13.78 0.08
78.8 %
Table 1 Novel predictors for OLT/death in DILI patients with acute liver
failure
References: 1. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G.
Drug-induced acute liver failure: results of a U.S. multicenter, prospective
study. Hepatology. 2010;52(6):2065-76.
2. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation
for acute liver failure from drug-induced liver injury in the United
States. Liver Transpl. 2004;10(8):1018-23.
3. Weber S, Benesic A, Neumann J, Gerbes AL. Liver injury associated with
metamizole exposure: features of an underestimated adverse event. Drug
Saf. 2021;2021 Feb 27. doi: 10.1007/s40264-021-01049-z. Epub ahead of
print.
4. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I,
Gonzalez-Jimenez A, et al. Use of Hy's law and a new composite algorithm
to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology.
2014;147(1):109-18 e5.
Disclosure: Nothing to disclose.
0.91
92.3 %
93.3 % 92.3 % 93.3 % 13.78 0.08
78.8 %
0.71
0.73
0.73
0.75
0.88
0.91
78.6 %
92.9 %
78.6 %
76.9 %
92.3 %
84.6 %
61.1 % 61.1 % 78.6 % 2.02
57.9 % 61.9 % 91.7 % 2.21
68.4 % 64.7 % 81.3 % 2.49
73.3 % 71.4 % 78.6 % 2.88
80.0 % 80.0 % 92.3 % 4.62
100 % 100 % 88.2 % na 1
0.35
0.12
0.31
0.32
0.10
0.17
Diagnostic
accuracy
(effectiveness)
66.7
%
72.7 %
72.7 %
63.6 %
72.7 %
78.8 %
Colorectal neoplasia: Characterisation and
treatment
10:00-11:00 / Hall 8
MP121
IS EARLY-ONSET COLORECTAL CANCER DIFFERENT ACCORDING TO
DISEASE LOCATION? ANALYSIS OF TUMOR CHARACTERISTICS, RISK
FACTORS AND CLINICAL OUTCOMES OF 385 GENETICALLY TESTED
PATIENTS
C. Foppa1, S. Tamburello1
A. Spinelli2,8
1
, M. Carvello1,2
A. Santoro2,5, V. Smiroldo5, C. Bonifacio6
, L. Laghi3,4
, L. Poliani4
IRCCS Humanitas Research Hospital, Division of Colon
and Rectal Surgery, Department of Surgery, Milan, Italy,
2
and Surgery, Parma, Italy, 4
Humanitas University, Department of Biomedical Sciences,
Milan, Italy, 3
University of Parma, Department of Medicine
Division of Gastroenterology, Milan, Italy, 5
IRCCS Humanitas Research Hospital,
IRCCS Humanitas
Research Hospital, Medical Oncology and Hepatology Unit,
Humanitas Cancer Center, Milan, Italy, 6
IRCCS Humanitas
Research Hospital, Division of Radiology, Milan, Italy, 7
IRCCS
Humanitas Research Hospital, Division of General and Digestive
Surgery, Milan, Italy, 8
IRCCS Humanitas Research Hospital,
Division of Colon and Rectal Surgery; Department of Surgery,
Milan, Italy
Contact E-Mail Address: caterina.foppa@gmail.com
Introduction: Although few is known about early-onset colorectal cancer
(EOCRC; <50 years), it has been hypothesized that it probably encompasses
different subclasses according to tumor location (right colon cancerRCC,
left colon cancer-LCC, rectal cancer-RC)1,2.
Aims & Methods: The study aims to compare demographics, histology
pattern, molecular features and outcomes between EO-RCC, EO-LCC and
EO-RC and to investigate risk factors for disease progression/recurrence
and death.
385 EOCRC operated between January 1st
, 2010 and March 31th, 2021 at
a tertiary center were included. Genetic testing was performed for all patients.
Results:
RCC were 84 (28% <39), LCC 130 (28.5% <39), and RC 171 (32.8%
<39). Baseline characteristics were comparable among groups, except for
female gender, predominant in LCC (p=0.026). RCC showed a higher rate
of mucinous tumors (30.9%, p<0.0001), a higher proportion of microsatellite
instability (23.8%; p<0.0001), and consequently of genetic syndromes
(21.4%; p=0.004). RCC and LCC had a higher rate of nodal (63.1% and
58.4% vs 40.3% of RC; p=0.004) and distal metastases (34.5% and 46.9%
vs 22.8%; p=0.0006). The rate of KRAS, NRAS, BRAF, PI3KCA mutations was
comparable. Cancer-Specific Survival (CSS) and Disease-Free Survival
(DFS) did not differ at a mean follow-up of 40 months.
The variables associated to disease recurrence or progression were age
< 39 (p=0.042), nodal (p=0.001), distant metastases (p<0.0001), mutations
(p=0.011), adjuvant therapy (p<0.0001), microsatellite stability status
(p=0.012), obesity (p=0.05). Variables associated to death were age < 39
(p<0.0001), male gender (p=0.013), mucinous component (p=0.001), nodal
(p<0.0001), distant metastases (p<0.0001); mutations (p<0.0001); adjuvant
therapy (p<0.0001).
Conclusion: EOCRC is more frequently left-sided. Right and left cancers
were more metastatic at diagnosis, however, CSS and DFS did not differ.
Genetic syndromes were more prevalent in RCC group. Age < 39 and the
presence of mutations were independent risk factor for progression and
death.
240
UEG Journal | Abstract Book
,
, M. Montorsi2,7, A. Maroli8
,
UEGJournal Abstracts 2021

Table of Contents for the Digital Edition of UEGJournal Abstracts 2021
